意大利2022-2024年HIV-1亚型传播性耐药NGS评估
研究收集2022至2024年意大利新诊断个体血浆HIV-1 RNA的NGS基因型数据,以10%和20%阈值评估传播性耐药(TDR)及基因型敏感性。
要点
- 意大利新诊断HIV-1中非B亚型占51.9%,以CRF02_AG最多。
- TDR患病率在>20%阈值下为11.7%,10%阈值下为15.0%。
- 除依非韦伦和利匹韦林外,多数药物在近99%个体中保持完全活性。
核心结论
- 意大利HIV-1非B亚型比例高,TDR患病率约12%(类似Sanger阈值)至15%(10%阈值),但对当前临床抗逆转录病毒药物的敏感性影响可忽略。
主要发现
- 任何类别的TDR患病率在类似Sanger的NGS设置(>20%)下为11.7%,在10% NGS设置下为15.0%,且在不同亚型间显著变化,B亚型最高。
- 大多数抗逆转录病毒药物在近99%个体中显示完全基因型活性,但依非韦伦和利匹韦林的完全活性比例低于92%。
- 在5个传播簇中TDR被检测为少数突变。
临床怎么用
- 临床实践中,尽管NGS检测到TDR,但对当前常用抗逆转录病毒药物的敏感性影响可忽略,提示现有治疗方案仍有效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Monitoring HIV-1 subtype circulation and transmitted drug resistance (TDR) remains a key priority, particularly since the rollout of high-sensitivity next-generation sequencing (NGS). METHODS: Routine plasma HIV-1 RNA NGS genotyping data were collected from newly diagnosed individuals in Italy over 2022-24. HIV-1 TDR and genotypic susceptibility were evaluated through HIVdb with NGS set at 10% and 20%. Subtype and transmission clusters (TC) were determined through the maximum likelihood phylogeny based on the GTR + F + R9 model. RESULTS: Seven hundred and forty-two individuals were included, 51.9% harbouring non-B strains [CRF02_AG (18.1%); CRF BF (6.1%); A1/A3/A6 (7.1%); others (20.5%)]. TDR prevalence to any class was 11.7% at Sanger-like NGS-setting (>20%), slightly increased (15.0%) at 10% NGS-setting, and significantly varied across subtypes, with the highest prevalence observed in B subtype. Most antiretrovirals showed full genotypic activity in nearly 99% of individuals, except for efavirenz and rilpivirine (proportion of individuals with full activity <92%). A total of 57 TC were detected: 40 pairs, 17 clusters (>2 sequences). Thirteen TC (22.8%, 8 pairs, 5 clusters) involved individuals harbouring TDR. TDR was detected as minority mutations in five TC. CONCLUSIONS: A high proportion of HIV-1 non-B subtypes circulate in Italy. TDR prevalence is around 12% using NGS at Sanger-like threshold and moderately increases to 15% when NGS is set at 10%. However, the impact of the detected TDR on the susceptibility to currently used antiretrovirals in clinical practice is negligible.
引用
- Armenia D, Alteri C, Micheli V, et al. Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing. J Antimicrob Chemother. 2026. PMID: 41826804. doi:10.1093/jac/dkag084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。